Skip to main content

Table 1 Clinical characteristics

From: Decreased level of serum carnitine might lead to arteriosclerosis progression via the accumulation of advanced glycation end products in maintenance hemodialysis patients

Number of patients (male/female) (n) 116 (65/51)
Age (years) 62 ± 13
Body mass index (kg/m2) 21.3 ± 3.3
Type 2 diabetes mellitus (+/−)(n) 48/68
Treatment (%)
 ARB/ACE inhibitor 31.0
 Iron therapy 37.1
Systolic blood pressure (mmHg) 149 ± 24
Diastolic blood pressure (mmHg) 88 ± 16
Heart rate (/min) 77 ± 12
Duration of hemodialysis (years) 7.6 ± .2
Kt/V (range) 1.10 ± 0.31
Hemoglobin A1c (%) 5.4 ± 0.7
Glycated albumin (%) 16.7 ± 3.8
Triglyceride (mg/dL) 139 ± 110
Total cholesterol (mg/dL) 169 ± 32
Low-density lipoprotein cholesterol (mg/dL) 94 ± 26
High-density lipoprotein cholesterol (mg/dL) 51 ± 19
Albumin (g/dL) 3.8 ± 0.3
Creatinine (mg/dL) 11.26 ± 3.08
Uric acid (mg/dL) 6.9 ± 1.4
Urea nitrogen (mg/dL) 62.9 ± 13.5
Corrected calcium (mg/dL) 9.0 ± 0.8
Phosphate (mg/dL) 5.7 ± 1.3
C-reactive protein (mg/dL) 0.27 ± 0.79
β2-microglobumin (mg/L) 24.9 ± 5.4
Total carnitine (μmol/L) 44.5 ± 11.7
Free carnitine (μmol/L) 28.6 ± 8.1
Acyl carnitine (μmol/L) 15.9 ± 4.7
Acyl carnitine/free carnitine 0.6 ± 0.1
Skin autofluorescence (arbitrary unit) 3.4 ± 0.7
Left ventricular ejection fraction (%) 66.9 ± 8.9
  1. Data are presented as mean ± standard deviation. Kt/V is used to evaluate the hemodialysis adequacy
  2. ARB angiotensin II receptor blocker, ACE inhibitor angiotensin-converting enzyme inhibitor